Artemis Medicare Services Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹282Cr
- +12.8% YoY
- +2.9% QoQ
- Net profit
- ₹31Cr
- +47.6% YoY
- +3.3% QoQ
- Margin
- 20%
- +4 pp YoY
- +2 pp QoQ
Guidance rank: #17 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
4 of 5 strong
The short version
Expansion to 900-950 beds at Gurgaon standalone facility in 18-22 months. Artemis Medicare Services projects reaching 70% occupancy by Q2 FY27, boosting revenue and profitability.
From Artemis Medicare Services Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Expansion to 900-950 beds at Gurgaon standalone facility in 18-22 months.
- Target occupancy of 70% by Q2 and 85% census in the medium term.
- Anticipated 4-5% ARPOB (Average Revenue Per Occupied Bed) growth.
- Potential to reach INR 2,000 crores topline from Gurgaon alone within 3-5 years.
- Launch of advanced tertiary and quaternary pediatric and obstetric care in new 200-bed expansion.
- Raipur facility showing encouraging early traction with multiple specialties active, growing OPD and surgery volumes.
- Focus on brownfield expansions via internal accruals and selective acquisitions (INR 700 crores enabling resolution).
2 more points from Artemis Medicare Services Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Artemis Medicare Services Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total capex planned over the next three years is approximately INR 800 crores, excluding deposits.
- Breakdown includes:
- INR 120 crores for Tower IV (200-bed expansion in Gurgaon with multi-level parking).
- INR 350-360 crores for VIMHANS hospital expansion.
- INR 120 crores for Raipur hospital (already operational).
- Additional deposit of INR 250 crores to VIMHANS, with INR 130 crores already paid.
- A 200+ bed advanced pediatric and obstetrics/gynecology facility to be operational in 18-22 months.
- Enabling resolution passed to raise up to INR 700 crores for potential brownfield acquisitions and strategic expansions, expected to be decided within 6-8 months based on asset finalization.
2 more points from Artemis Medicare Services Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Artemis Medicare Services Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Artemis Medicare Services Ltd's call on order book
Create a free account to keep reading this call
Artemis Medicare Services Ltd — Quarterly revenue & net profit
Artemis Medicare Services Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 282 | 250 | +12.8% | 274 | +2.9% |
| Operating profit (EBITDA) | 55 | 41 | +34.1% | 50 | +10% |
| Operating margin | 20% | 16% | +4 pp | 18% | +2 pp |
| Profit before tax | 42 | 30 | +40% | 39 | +7.7% |
| Net profit (PAT) | 31 | 21 | +47.6% | 30 | +3.3% |
| EPS (₹) | 1.96 | 1.54 | +27.3% | 1.87 | +4.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹306 Cr, net profit ₹31 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Artemis Medicare's management said in earlier quarters
Others in Healthcare Services this season
- Aatmaj Health (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
- Asarfi Hospital (Q1 FY27)
Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q
- KMC Speciality (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- 3B Blackbio (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Artemis Medicare Services Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Artemis Medicare Services Ltd Q1 FY27 results?
Expansion to 900-950 beds at Gurgaon standalone facility in 18-22 months. Artemis Medicare Services projects reaching 70% occupancy by Q2 FY27, boosting revenue and profitability.
What is Artemis Medicare Services Ltd share price analysis?
Artemis Medicare Services Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 42.0 with a market cap of ₹4,850 Cr. Investors should review the full earnings analysis for detailed insights.
Is Artemis Medicare Services Ltd planning capital expenditure?
Total capex planned over the next three years is approximately INR 800 crores, excluding deposits.
Keep Artemis Medicare Services Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
